NCT00655837View on ClinicalTrials.gov

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Lymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Interventions
DRUG

SGN-40

4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.

DRUG

rituximab

375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.

DRUG

gemcitabine

1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania, Philadelphia

27710

Duke University Medical Center, Durham

60068

Oncology Specialists, Park Ridge

63110

Washington University School of Medicine, St Louis

85259

Mayo Clinic Arizona, Scottsdale

89135

Nevada Cancer Institute, Las Vegas

35294-3300

University of Alabama at Birmingham, Birmingham

80045-0510

University of Colorado, Aurora

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Seagen Inc.

INDUSTRY